A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Hospital Clínic de Barcelona, Barcelona

MD Anderson Cancer Center Madrid, Madrid

Hospital San Pedro de Alcantara, Cáceres

Memorial Sloan Kettering Cancer Center, New York

Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital Universitario 12 de Octubre, Madrid

The Blood and Marrow Transplant Group of Georgia, Atlanta

Hospital Universitari i Politècnic La Fe, Valencia

Froedtert Hospital, Milwaukee

University of Chicago Medical Center, Chicago

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

University of Texas MD Anderson Cancer Center, Houston

Oregon Health and Science University, Portland

University of California Los Angeles (UCLA), Los Angeles

Hospital Germans Trias i Pujol, Barcelona

Hospital Universitari Vall d'Hebrón, Barcelona

Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona